NDAINTRAVENOUSPOWDER
Approved
Jan 2023
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
2/8 — Basic
TECHNETIUM TC 99M MERTIATIDE KIT (technetium tc 99m mertiatide) by Jubilant Therapeutics is imaging, technetium tc 99m mertiatide is rapidly cleared from the blood. First approved in 2023.
Drug data last refreshed 32m ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Technetium Tc 99m Mertiatide is a diagnostic imaging agent administered intravenously as a reconstituted powder kit. It is rapidly cleared from blood and excreted through the kidneys and urine, enabling renal imaging and function assessment. This is a nuclear medicine tracer used for diagnostic imaging purposes in patients requiring kidney imaging evaluation.
Peak
Recent approval (Jan 2023) positions this in peak commercial expansion phase; competitive pressure at 30% suggests moderate but growing market intensity requiring specialized nuclear medicine expertise.
Mechanism of Action
imaging, Technetium Tc 99m Mertiatide is rapidly cleared from the blood. It is cleared by the kidneys and excreted in the urine.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
This newly approved (Jan 2023) diagnostic imaging agent offers career opportunities in a specialized nuclear medicine market with moderate competitive intensity. Roles focus on commercialization, market access, and clinical adoption with MSL and field teams engaging specialized imaging centers and nuclear medicine departments.
Product ManagerCommercial Manager
Worked on TECHNETIUM TC 99M MERTIATIDE KIT at Jubilant Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.